The role of multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy in active surveillance for low-risk prostate cancer: A systematic review
- PMID: 32774849
- PMCID: PMC7398967
- DOI: 10.1016/j.amsu.2020.07.015
The role of multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy in active surveillance for low-risk prostate cancer: A systematic review
Abstract
The performance of multiparametric magnetic resonance imaging (mpMRI) and subsequent biopsy in monitoring prostate cancer in men on active surveillance (AS) have not been defined clearly. In this systematic review, we aimed to review current literature about the usage of MRI examination in men with low-risk prostate cancer during active surveillance. For that, we searched seven databases to include all studies reporting magnetic resonance imaging in the AS of low-risk prostate cancer. We finally included 11 studies with 1237 patients included. Our results showed an adequate sensitivity and specificity of both modalities to detect disease progression; including disease upgrading and upstaging. However, the performance in the prediction of unfavorable disease was inferior to the detection of upgrading and upstaging. In terms of MRGB, the previous literature agreed on the superiority of using a combination of different biopsy schemes to get a better progression section. Noteworthy, mp-MRI and MRGB had a good predictive value limited to the first year, with TRUSGB showing a superior role in detecting patients with a GS ≥ 7, after that. In conclusion, both of mpMRI and MRGB have shown an adequate performance on assessing disease progression in the AS of low-risk prostate cancer patients. They can be used for disease staging and grading for successful treatment planning.
Keywords: Active surveillance; MRGB; MRI; Prostate cancer.
© 2020 The Authors.
Conflict of interest statement
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Figures
Similar articles
-
Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.Eur Urol Focus. 2019 May;5(3):407-415. doi: 10.1016/j.euf.2017.12.008. Epub 2018 Jan 10. Eur Urol Focus. 2019. PMID: 29331622
-
Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.Eur Urol. 2014 Jul;66(1):22-9. doi: 10.1016/j.eururo.2014.03.002. Epub 2014 Mar 14. Eur Urol. 2014. PMID: 24666839
-
Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.Invest Radiol. 2014 Mar;49(3):165-72. doi: 10.1097/RLI.0000000000000008. Invest Radiol. 2014. PMID: 24220253
-
MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature.World J Urol. 2019 Jul;37(7):1263-1279. doi: 10.1007/s00345-018-2497-y. Epub 2018 Sep 25. World J Urol. 2019. PMID: 30255394 Review.
-
Multiparametric MRI in detection and staging of prostate cancer.Dan Med J. 2017 Feb;64(2):B5327. Dan Med J. 2017. PMID: 28157066 Review.
Cited by
-
Appropriateness of Imaging for Low-Risk Prostate Cancer-Real World Data from the Pennsylvania Urologic Regional Collaboration (PURC).Curr Oncol. 2024 Aug 20;31(8):4746-4752. doi: 10.3390/curroncol31080354. Curr Oncol. 2024. PMID: 39195337 Free PMC article.
References
-
- UPST Force. Screening for prostate cancer: US preventive services task force recommendation statement. Ann. Intern. Med. 2008;149(3):185. - PubMed
-
- Hamdy F.C., Donovan J.L., Lane J., Mason M., Metcalfe C., Holding P. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 2016;375:1415–1424. - PubMed
-
- Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412(6849):822–826. - PubMed
-
- Loeb S., Vellekoop A., Ahmed H.U., Catto J., Emberton M., Nam R. Systematic review of complications of prostate biopsy. Eur. Urol. 2013;64(6):876–892. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials